세계의 만성 비부비동염 시장(2023-2030년)

Market Overview

Global Chronic Rhinosinusitis Market reached US$ 2.6 billion in 2022 and is expected to reach US$ 4.5 billion by 2030, growing with a CAGR of 7.3% during the forecast period 2023-2030.

The global chronic rhinosinusitis market experiencing significant growth in recent years with various factors influencing its dynamics such as increasing prevalence, rising clinical trials for better treatment, and others. Government investments in the development of better treatment options will continue to drive and boost the global chronic rhinosinusitis market. The global industry is placing increasing emphasis on sustainable practices to reduce its impact.

Moreover, there is no cure for chronic rhinosinusitis, but the disease can be managed by using different types of medical devices such as nasal irrigation devices and other medical devices, drugs like steroids pills, antibiotics, biologics, and other drugs, nasal steroid sprays, and nasal drops. In severe situations, surgery is considered for better management of associated symptoms. Nasal steroid sprays are most commonly used for better management and they are considered as safe.

Similarly, North America dominates the chronic rhinosinusitis market, capturing the largest market share owing to the region's favorable reimbursement policies, increasing prevalence, advanced and well-established healthcare infrastructure, and presence of major players.

Owing to the increasing prevalence of chronic rhinosinusitis, increasing awareness, rising clinical trials, increasing demand for novel therapeutics, increasing adoption of personalized medicines, rising demand for minimally invasive procedures, and advancements in treatment options are the major factors expected to drive the global chronic rhinosinusitis market over the forecast period.

Market Dynamics

Rising Clinical Trials are Expected to Drive the Growth of the Chronic Rhinosinusitis Market

The increasing number of clinical trials on chronic rhinosinusitis is expected to drive the market over the forecast period. Clinical trials are mainly performed to know the safety and efficacy of new drugs, medical devices, and other therapeutics and also provide valuable insights into the underlying mechanisms of chronic rhinosinusitis. The positive clinical trials encourage patients for using novel therapeutics.

For instance, For instance, on February 22, 2022, Biohaven Pharmaceutical Holding Company Ltd., a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, announced that it has commenced enrollment in a Phase 2/3 clinical trial assessing the efficacy and safety of Nurtec ODT (rimegepant) 75 mg in patients with chronic rhinosinusitis (CRS) with or without nasal polyps.

Moreover, the positive trial results can also lead to the approval and introduction of novel treatment options by expanding the range of treatment choices available to patients for better and enhanced management of chronic rhinosinusitis. The clinical trials also engage the opportunities to perform research activities for more advanced treatments, which results in better management of the disease and improved patient outcomes.

For instance, on September 8, 2022, Lyra Therapeutics, Inc., a clinical-stage therapeutics company leveraging its proprietary XTreo platform to enable precise, sustained, and local delivery of medications to the ear, nose, and throat (ENT) passages and other diseased tissues, announced the enrollment of the first patient in the Phase 3 ENLIGHTEN II clinical trial of LYR-210 in adult patients with chronic rhinosinusitis (CRS). LYR-210 is designed as an alternative to sinus surgery for the millions of CRS patients that remain symptomatic despite treatment.

Increasing Awareness of Chronic Rhinosinusitis and Their Associated Treatments Expected to Drive the Growth of the Market

Increasing awareness of chronic rhinosinusitis and its associated treatments is expected to drive the market over the forecast period. The increased awareness can help individuals recognize the symptoms of chronic rhinosinusitis at an earlier stage. This can lead to quicker medical consultations, early diagnosis, and better management. The increasing awareness also improves care and better patient outcomes.

For instance, on April 20, 2023, EUFOREA announced the launch of its 2nd annual Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Awareness Day on April 20 2023 in Brussels, Belgium. The aims of this campaign include raising awareness of CRSwNP and comorbidities, encouraging healthcare professionals at all levels to provide specialist care, and educating patients on the symptoms of CRSwNP.

Moreover, many people with chronic rhinosinusitis may not realize they have the condition, attributing their symptoms to other factors. This increased awareness through awareness campaigns can help individuals to understand that their symptoms could be indicative of a medical condition, leading to proper diagnosis and treatment. The increased awareness also increases the demand for novel treatment options.

Increasing Regulatory Approvals Also Expected to Drive the Growth of the Chronic Rhinosinusitis Market

Increasing regulatory approvals drive the growth of the market over the forecast period by enabling the introduction of new treatment options for the management of chronic rhinosinusitis. This can further provide the patients with enhanced and better treatment options. The regulatory approvals increase the development of innovative treatment options by addressing the unmet needs associated with chronic rhinosinusitis treatment.

For instance, on May 04, 2023, Optinose, a pharmaceutical company focused on patients treated by ear, nose, and throat (ENT) and allergy specialists, announced the U.S. Food and Drug Administration (FDA) accepted for review its supplemental new drug application requesting approval of XHANCE as a treatment for chronic rhinosinusitis. XHANCE (fluticasone propionate) nasal spray is a drug-device combination product that combines the most widely used nasal anti-inflammatory drug with the innovative Exhalation Delivery System (EDS).

Additionally, regulatory approvals also allows the approved treatments to become accessible to a larger patient population, which shows promising results for the better management of the symptoms. This can lead to better disease management, improved quality of life, and reduced healthcare burdens which are associated with chronic rhinosinusitis.

For instance, on July 29, 2021, GlaxoSmithKline plc (GSK) announced that the US Food and Drug Administration has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This new indication for mepolizumab is for the add-on maintenance treatment of CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

Lack of Funding and Investments Will Hamper the Market's Growth

The lack of funding and investments in chronic rhinosinusitis is expected to hamper the market growth over the forecast period. Adequate funding is crucial for conducting research activities into the causes, mechanisms, and potential treatments for chronic rhinosinusitis. Without sufficient funding, researchers face challenges to conduct clinical trials, developing new therapies, and exploring innovative treatment approaches.

Moreover, developing new medications for chronic rhinosinusitis is very crucial to address the unmet needs and that requires significant investment in research and development. The lack of funding and investments sometimes leads to delays in drug development and approval processes, which in turn can limit the availability of new and more effective treatments for patients. So proper funding and investments are very crucial.

Stringent Pricing of the Treatment Will Also Hampers the Market Growth

The stringent treatment costs are expected to hamper the market share over the forecast period. High pricing can limit access for many chronic rhinosinusitis patients who are seeking better and curable treatment, especially for people with limited insurance coverage. This high treatment cost makes patients unaffordable for proper management of chronic rhinosinusitis. This can results in the hampering the market growth over the forecast period.

The high treatment costs also hamper the research activities and clinical trials for novel therapeutics. Even among patients who initially start treatment, high costs may lead to reduced treatment adherence. This can result in suboptimal outcomes, as consistent and continuous treatment is often necessary for the best results in the management of chronic rhinosinusitis and its associated risks.

Segment Analysis

The global chronic rhinosinusitis market is segmented based on disease phenotype, treatment type, distribution channel, end-user and region.

The Steroid Nasal Sprays from the Treatment Type Segment Accounted for Approximately 45.3% of the Chronic Rhinosinusitis Market Share

Steroid nasal sprays hold the largest market share over the forecast period by playing a crucial role in the management of chronic rhinosinusitis. Steroid nasal sprays such as mometasone (also known as Nasonex) and fluticasone (Avamys or Flixonase) are very commonly used medications in the nasal sprays for chronic rhinosinusitis. Steroid nasal sprays are anti-inflammatory medications helps to suppress the immune response in chronic rhinosinusitis.

For instance, on May 3, 2023, Bausch Health Companies Inc. is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS (olopatadine hydrochloride and mometasone furoate (medium-strength corticosteroid) nasal spray).

Moreover, steroid nasal sprays are primarily used in the management of chronic rhinosinusitis due to their promising results. Unlike oral corticosteroids, which can have significant systemic side effects when taken in higher doses or over a prolonged period, nasal sprays deliver the medication directly to the nasal passages with minimal side effects. This reduces the likelihood of systemic side effects and increases the adoption and wide acceptability.

Geographical Penetration

North America Accounted for Approximately 39.5% of the Market Share in 2022, Owing to the Increasing Prevalence and Strong Presence of Major Players

North America region is expected to hold the largest market share over the forecast period mainly owing to the increasing prevalence of chronic rhinosinusitis and the strong presence of major players in the region. There is a continuously increasing prevalence of chronic rhinosinusitis due to the largest population in the region. For instance, according to the NIH, chronic rhinosinusitis (CRS) is one of the most common chronic medical conditions worldwide, affecting all age groups. Its estimated incidence is 12.3% in the USA.

Moreover, in North America, especially in the United States and Canada, there is a strong presence of major players including pharmaceutical companies and research institutes that majorly focus on the development of novel therapeutics for the management of chronic rhinosinusitis. These major players are also actively performing the clinical trials and research activities.

For instance, on March 14, 2022, AstraZeneca announced that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).

Competitive Landscape

The major global players in the chronic rhinosinusitis market include Lyra Therapeutics, Novartis, Medtronic plc, GlaxoSmithKline plc, AstraZeneca, Sanofi, Dr. Reddy's Laboratories Ltd., Stryker Corporation, Bayer AG, and Smith & Nephew among others.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global chronic rhinosinusitis market. During the pandemic, many clinical trials, research activities, and regulatory approvals have been temporarily postponed due to the redirected focus towards the COVID-19 pandemic and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations worldwide. Many hospitals are focused on the COVID-19 cases, which further reduced nasal related treatments including chronic rhinosinusitis treatment and management of the symptoms.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials such as nasal sprays, nasal drops, and medical devices. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks.

Overall, telecommunication is a major focussing part during the COVID-19, which positively impacted the market. This telecommunication allows patients with timely diagnoses and better treatment with reduced consultation costs and time. It is mainly useful for patients who are living in remote areas.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global chronic rhinosinusitis market. Many clinical trials and research activities of chronic rhinosinusitis are temporarily disrupted due to conflict-related issues. The conflict has less impact mainly due to the low prevalence and absence of key market players in this region.

By Disease Phenotype

• Non-Eosinophilic Chronic Rhinosinusitis
• Eosinophilic Chronic Rhinosinusitis
• Infectious Chronic Rhinosinusitis
• Allergic Fungal Rhinosinusitis
• Others

By Treatment Type

• Medical Devices
• Nasal Irrigation Devices

Squeeze Bottle Devices

Syringes

Neti Pots

Others

• Exhalation Delivery Systems
• Steroid-Eluting Stents
• Drugs
• Steroid Pills
• Antibiotics
• Leukotriene Modifiers
• Biologics
• Others
• Nasal Drops
• Steroid Nasal Sprays
• Surgery
• Endoscopic Sinus Surgery
• Functional Endoscopic Sinus Surgery
• Sinus Septoplasty
• Others
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Region

• North America

U.S.

Canada

Mexico

• Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

• South America

Brazil

Argentina

Rest of South America

• Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

• Middle East and Africa

Key Developments

• On June 02, 2023, Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing innovative therapies for the localized treatment of chronic rhinosinusitis (CRS), announced that it has issued an equity-based award pursuant to its 2022 Inducement Award Plan to its Senior Vice President of Regulatory Affairs, Allison Nance, upon the commencement of her employment. The inducement grant consists of a non-qualified stock option to purchase an aggregate of 110,000 shares of the Company's common stock.
• On February 9, 2023, H2Ocean LLC published a clinical study on the efficacy of their sea salt-based nasal spray, Nasalzyme, which can relieve the symptoms of chronic rhinosinusitis. H2Ocean's Nasalzyme, a non-addictive nasal spray made of all-natural ingredients, including unrefined sea salt harvested from the Red Sea, and naturally occurring enzymes contains key components that act to relieve chronic rhinosinusitis and other sinus conditions.
• On October 14, 2022, Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company, announced that dosing has begun in Phase I clinical study to compare the pharmacokinetics and safety of BAT2606, a proposed biosimilar of Nucala (mepolizumab), to US-sourced and EU-sourced reference product in normal healthy volunteers. The clinical study is a randomized, double-blind, parallel-group, single-dose study that is expected to enroll approximately 207 healthy volunteers.

DataM Intelligence Opinion:

According to the DataM Intelligence, the chronic rhinosinusitis market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence and as there is no cure for this disease but, novel therapeutic innovations are developing for better patient outcomes. Many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many clinical trials and research activities are still going on for novel therapeutics, which is expected to growth of the global chronic rhinosinusitis market in the upcoming years.

Why Purchase the Report?

• To visualize the global chronic rhinosinusitis market segmentation based on disease phenotype, treatment type, distribution channel, end-user, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of chronic rhinosinusitis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global chronic rhinosinusitis market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Disease Phenotype
• 3.2. Snippet by Treatment Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by End-User
• 3.5. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Clinical Trials
    • 4.1.1.2. Increasing Awareness of Chronic Rhinosinusitis and Their Associated Treatment Options
    • 4.1.1.3. Increasing Regulatory Approvals
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Funding and Investments
    • 4.1.2.2. Stringent Pricing for the Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Disease Phenotype

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
  • 7.1.2. Market Attractiveness Index, By Disease Phenotype
• 7.2. Non-Eosinophilic Chronic Rhinosinusitis *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Eosinophilic Chronic Rhinosinusitis
• 7.4. Infectious Chronic Rhinosinusitis
• 7.5. Allergic Fungal Rhinosinusitis
• 7.6. Others

8. By Treatment Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 8.1.2. Market Attractiveness Index, By Treatment Type
• 8.2. Medical Devices *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.2.3. Nasal Irrigation Devices
    • 8.2.3.1. Squeeze Bottle Devices
    • 8.2.3.2. Syringes
    • 8.2.3.3. Neti Pots
    • 8.2.3.4. Others
  • 8.2.4. Delivery Systems
  • 8.2.5. Exhalation Steroid-Eluting Stents
• 8.3. Drugs
  • 8.3.1. Steroid Pills
  • 8.3.2. Antibiotics
  • 8.3.3. Leukotriene Modifiers
  • 8.3.4. Biologics
  • 8.3.5. Others
• 8.4. Nasal Drops
• 8.5. Steroid Nasal Sprays
• 8.6. Surgery
  • 8.6.1. Endoscopic Sinus Surgery
  • 8.6.2. Functional Endoscopic Sinus Surgery
  • 8.6.3. Sinus Septoplasty
  • 8.6.4. Others
• 8.7. Others

9. By Distribution Channel

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.1.2. Market Attractiveness Index, By Distribution Channel
• 9.2. Hospital Pharmacies *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Ambulatory Surgical Centers
• 10.5. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.7.1. U.S.
    • 11.2.7.2. Canada
    • 11.2.7.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.7.1. Germany
    • 11.3.7.2. UK
    • 11.3.7.3. France
    • 11.3.7.4. Italy
    • 11.3.7.5. Spain
    • 11.3.7.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. Brazil
    • 11.4.7.2. Argentina
    • 11.4.7.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. China
    • 11.5.7.2. India
    • 11.5.7.3. Japan
    • 11.5.7.4. Australia
    • 11.5.7.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Phenotype
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Lyra Therapeutics *
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Financial Overview
  • 13.1.4. Key Developments
• 13.2. Novartis
• 13.3. Medtronic plc
• 13.4. GlaxoSmithKline plc
• 13.5. AstraZeneca
• 13.6. Sanofi
• 13.7. Dr. Reddy's Laboratories Ltd.
• 13.8. Stryker Corporation
• 13.9. Bayer AG
• 13.10. Smith & Nephew

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us